For INPP4B, loss of expression or mutations were found in 8% and 47% of primary tumors and metastases respectively, while for PTEN similar changes were found in 4% of primary tumors and 42% of metastases suggesting a tumor suppressor role for INPP4B in prostate cancer [42]. Here, PTEN is linked to prostate carcinoma.